Multi Cohort Study of Tazemetostat in Combination With Various Treatments For R/R Hematologic Malignancies
Status:
Recruiting
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
This phase 1b/2 trial studies how safely the EZH2 inhibitor tazemetostat works with other
therapies in various hematological malignancies. Tazemetostat has been found to be a safe and
effective drug that works in patients with relapsed refractory follicular lymphoma. Giving
tazemetostat in combination with other treatments may work better in treating patients with
hematological malignancies and may improve disease response and durability of response.